Sermorelin — compound monograph
Growth-hormone-releasing hormone fragment analogue. Discontinued. The Institute assesses 2 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Sermorelin
- Compound class
- Growth-hormone-releasing hormone fragment analogue
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- GRF(1-29) · geref · sermorelin acetate · sermorelin (INN)
- Route as evaluated
- Subcutaneous or intravenous
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 86168-78-7
- Molecular formula
- C149H246N44O42S
- Average mass
- 3357.93
- Monoisotopic mass
- 3355.75
- ATC classification
- V04CD05 · H01AC05
§1.3Sequence and structural notes
The N-terminal 29 residues of human growth-hormone-releasing hormone, amidated at the C-terminus. GRF(1-29) retains the full biological activity of the 44-residue parent, which makes it the minimal active fragment. It lacks any DPP-4-protecting modification and is therefore cleaved rapidly in plasma.
§1.4Assessment status
The Institute assesses Sermorelin across 2 indications and grades the strongest of them at low certainty. Clinical development was terminated. The Institute treats a discontinued programme as evidence.
Table 1. Assessed outcomes for Sermorelin, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | Peak stimulated growth hormone response used diagnostically; a peak below 5 µg/L after sermorelin supports pituitary rather than hypothalamic origin… | Moderate | 1 |
| Biological ageing and healthspan endpoints | No randomised human evidence identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.